N@N

Market Maker Surveillance Report. CAAS, KFS, XOMA, AEN, MSHL, JGBO, Losing Stocks With Lowest Price Friction For Wednesday, Ma

March 23, 2011 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 2480 companies with "abnormal" market making, 2816 companies with positive Friction Factors and 2301 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Wednesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. CHINA AUTOMOTIVE SYSTEMS INC (NASDAQ:CAAS), KINGSWAY FINANCIAL SERVICES (NYSE:KFS), XOMA LTD (NASDAQ:XOMA), ADEONA PHARMACEUTICALS INC (AMEX:AEN), MARSHALL EDWARDS INC (NASDAQ:MSHL), JIANGBO PHARMACEUTICALS INC (OTCBB:JGBO). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

     Symbol     Change       Percent      Buy Volume      Buy %%       Sell Volume     Sell %%      Net Volume      Friction
     CAAS       $-1.090      -12.41%      418,605         42.66%       560,991         57.17%       -142,386        -1,306  
     KFS        $-0.190      -17.58%      211,178         44.29%       262,340         55.02%       -51,162         -2,693  
     XOMA       $-1.500      -29.88%      2,923,756       46.64%       3,339,711       53.28%       -415,955        -2,773  
     AEN        $-0.210      -12.00%      556,219         38.70%       831,104         57.83%       -274,885        -13,090 
     MSHL       $-0.300      -16.21%      48,117          29.41%       115,492         70.59%       -67,375         -2,246  
     JGBO       $-0.640      -12.19%      40,676          37.51%       67,656          62.39%       -26,980         -422    

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net dollar losses (Change) and extremely low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows CAAS with a dollar loss Wednesday of $-1.09000 and a Friction Factor of -1,306 shares. That means that it only took 1,306 more shares of selling than buying to move CAAS lower by one penny. This means the Market Makers are allowing the stock to drop quickly (low friction). The combination of low friction and negative market direction can drive prices lower faster than normal.

CHINA AUTOMOTIVE SYSTEMS INC (NASDAQ:CAAS) - China Automotive Systems, Inc., through its interests in Sino-foreign joint ventures, engages in the manufacture and sale of power steering systems and other component parts for the automotive industry in the Peoples Republic of China. It offers a range of steering system parts for passenger automobiles and commercial vehicles. The company provides 4 separate series, 307 models of power steering, including rack and pinion power steering, integral power steering, electronic power steering and manual steering, steering columns, steering oil pumps, and steering hoses. China Automotive Systems, Inc. was founded in 2003 and is headquartered in Jing Zhou City, the Peoples Republic of China.

KINGSWAY FINANCIAL SERVICES (NYSE:KFS) - Kingsway Financial Services Inc. provides insurance solutions to individuals and businesses in the United States. The company primarily offers non-standard automobile insurance that covers drivers who do not qualify for standard automobile insurance coverage because of their payment history, driving record, place of residence, age, vehicle type, or other factors, as well as provides commercial automobile insurance products. It distributes its products through a network of independent agents. The company was founded in 1989 and is based in Mississauga, Canada.

XOMA LTD (NASDAQ:XOMA) - XOMA Ltd., incorporated in 1981, is a biopharmaceutical company in the field of therapeutic antibody discovery and development. The Company has a royalty interest in one approved therapeutic antibody, RAPTIVA, which is marketed in the United States, Europe and elsewhere, for the treatment of moderate-to-severe plaque psoriasis. XOMA also has a future royalty interest in additional therapeutic antibody product candidates being developed by others as a result of licensing its technologies. XOMA's pipeline includes both products and collaborative programs at various stages of preclinical and clinical development primarily directed toward treatments for cancer and immune disorders. In addition to supporting its product pipeline, the Company uses its infrastructure to provide process development and manufacturing services on a fee-for-service basis.

RAPTIVA (Efalizumab)

The Company markets RAPTIVA under an agreement with Genentech, Inc. as a result of a prior collaborative product development program. RAPTIVA is a humanized therapeutic monoclonal antibody developed to treat immune system disorders. RAPTIVA can be self-administered by patients as a single, once-weekly subcutaneous injection. In 2005, Serono had launched RAPTIVA in over 40 countries worldwide.

RAPTIVA competes with Enbrel from Amgen Inc. and its partner Wyeth Pharmaceuticals; Amevive from Biogen Idec Inc.; BG-12 from Biogen Idec Inc. and Fumapharm AG; Remicade from Centocor, Inc. Humira from Abbott Laboratories, and ISA247 from Isotechnika, Inc.

CHIR-12.12

CHIR-12.12, which is being developed by the Company in collaboration with Chiron Corporation, is an anti-CD40 antagonist antibody intended as a treatment for B-cell malignancies. In April 2005, XOMA announced the initiation of Phase I study for patients with advance chronic lymphocytic leukemia (CLL). Then in October 2005, the Company initiated a second Phase I study for patients with multiple myeloma (MM).

NEUPREX (opebacan/rBPI21)

NEUPREX (opebacan/rBPI21) is an injectable formulation of rBPI21, a modified recombinant fragment of human bactericidal/permeability-increasing protein (BPI). BPI is a human host-defense protein made by a type of white blood cell that is involved in the body's defenses against microbial infection. In October of 2003, in conjunction with Children's Medical Center Dallas, the Company announced the initiation of an open-label, single center, dose escalation, investigator-sponsored, Phase I/II clinical trial of NEUPREX in pediatric patients with congenital heart abnormalities requiring open heart surgery associated with cardiopulmonary bypass.

XMA005.2

XMA005.2 is a Human Engineered monoclonal antibody with a high-affinity and potent inhibitory activity against its inflammatory target. This high potency means that it may be suitable for use as a monthly-dose injectable therapeutic. XOMA is evaluating XMA005.2 in preclinical studies targeting multiple indications, including osteoarthritis and rheumatoid arthritis, where less frequent dosing could be a significant marketing advantage.

Anti-gastrin Mab

In September of 2004, XOMA announced a worldwide collaboration with Aphton Corporation to develop treatments for gastrointestinal (GI) and other gastrin-sensitive cancers using anti-gastrin monoclonal antibodies. Gastrin has been shown to be involved in the progression of colorectal, stomach, liver and pancreatic cancers and inhibiting gastrin may inhibit such growth.

Metabolic Disease Target

The Company is co-developing Metabolic Disease Target with Lexicon Genetics. Metabolic Disease Target is a secreted protein involved in metabolic functions such as insulin sensitivity and weight gain that was identified through Lexicon's Knockout Technology. Antibodies to this target may be developed to treat Type II diabetes, obesity and other metabolic diseases.

MLN2222

MLN2222 (also known as CAB2) is being developed by XOMA in partnership with Millennium Pharmaceuticals, Inc. MLN2222 is a complement inhibitor for coronary artery bypass graft surgery tar

ADEONA PHARMACEUTICALS INC (AMEX:AEN) - Adeona Pharmaceuticals, Inc. operates as a pharmaceutical company that develops medicines for central nervous systems and autoimmune diseases. It primarily focuses to in-license clinical-stage drug candidates that have already demonstrated a certain level of clinical efficacy and develop them further to either commercialization or development collaboration. The company is developing various clinical-stage drug candidates that include Trimesta, an investigational oral drug for the treatment of relapsing remitting multiple sclerosis; Zinthionein, an oral, gastro-retentive, and sustained-release medical food candidate for the dietary management of Alzheimers disease and mild cognitive impairment; and Effirma, a centrally-acting investigational oral drug for the treatment of fibromyalgia syndrome. It is also developing dnaJP1, an investigational oral drug for the treatment of rheumatoid arthritis; and CD4 Inhibitor 802-2, an investigational drug for the prevention of severe graft-versus-host disease. In addition, the company engages in commercializing serum-based diagnostic tests, including the CopperProof Panel to assist physicians in identifying patients with zinc deficiency and patients at risk of chronic copper toxicity due to impaired serum copper binding. Further, it involves in the manufacture, testing, and clinical development of tetrathiomolybate for Alzheimers, Parkinsons, and Huntingtons diseases. Adeona Pharmaceuticals, Inc. has a partnership with Meda AB, to develop flupirtine for the treatment of fibromyalgia syndrome. The company was founded in 2001 and is headquartered in Ann Arbor, Michigan.

MARSHALL EDWARDS INC (NASDAQ:MSHL) - Marshall Edwards, Inc., a developmental stage pharmaceutical company, engages in the development and commercialization of drugs for the treatment of cancer in the United States and Australia. The company involves in the clinical development and commercialization of its phenoxodiol drug candidates for the treatment of cancer; triphendiol, a signal transduction inhibitor for the treatment of pancreas and bile duct cancers, and melanoma; NV-143, an investigational anti-cancer drug to sensitize melanoma cell lines to the standard of care drug, dacarbazine, and members of the platinum drug family; and NV-128, an investigational cancer compound to promote cancer cell death by targeting the specific protein regulatory pathway in ovarian cancer cells. It is also conducting a Phase II prostate cancer clinical trial using phenoxodiol. The company was founded in 2000 and is based in North Ryde, Australia. Marshall Edwards, Inc. is a subsidiary of Novogen Limited.

JIANGBO PHARMACEUTICALS INC (OTCBB:JGBO) - Jiangbo Pharmaceuticals, Inc. engages in the research, development, production, marketing, and sale of pharmaceutical products in China. It produces western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup, and electuary (sticky syrup) forms. The company was formerly known as Genesis Pharmaceuticals Enterprises, Inc. and changed its name to Jiangbo Pharmaceuticals, Inc. in April 2009. Jiangbo Pharmaceuticals, Inc. was founded in 2003 and is based in Laiyang City, the People's Republic of China.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net